Posters

Corneal collagen cross-linking with iontophoresis (I-CXL): 12 months of follow-up study

Poster Details

First Author: E. Interlandi ITALY

Co Author(s):    F. Pellegrini   C. Gabriella   C. Gianluca   P. Giovanni           

Abstract Details

Purpose:

to assess long-term efficacy and safety of transepithelial corneal collagen cross-linking with iontophoresis (I-CXL) in patients affected by progressive keratoconus after 12 months of follow-up.

Setting:

Ophthalmology Department, “De Gironcoli” Hospital of Conegliano (TV), Italy.

Methods:

clinica data from 37 patients (39 eyes) affected by progressive keratoconus treated by I-CXL were retrospectively analyzed. In all cases I-CXL was performed with Iontofor-CXL device and riboflavin 0,1% RICROLIN+ (SOOFT Italia S.p.A.). BCVA, corneal astigmatism, maximum keratometry (Kmax), thinnest corneal thickness, measured by Pentacam, were analyzed at baseline and at 3, 6 and 12 months after surgery. Endothelium cell count was measured in all patients before surgery and at 12 months postoperatively. The occurrence of I-CXL related side effects was moreover evaluated.

Results:

the mean age of recruited patients (24 males and 13 females) at surgery time was 24,72 years (7,13 SD) including six patients younger than 18 years (range: 12 to 17 years). After 12 months of follow-up BCVA, even not significantly, slightly improved in 53,8% of treated eyes (p=0.1267). Corneal astigmatism and thickness at the thinnest point remained stable while K max significantly improved in 74,3 % of eyes with a final mean value of 49,54D (4,49 SD) compared with 53,80D (5,09 SD) at baseline (p=0,00019). None of the patients showed progression of keratoconus neither I-CXL related adverse effects during whole follow-up.

Conclusions:

The results of this study demonstrated I-CXL with RICROLIN+ to be an effective and safe procedure able to stabilize clinical course and to improve significantly Kmax value of our patients after one-year follow-up. I-CXL can be considered a valid conservative approach in patients affected by progressive keratoconus.

Financial Disclosure:

NONE